A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

OBJECTIVE: CHF5633 (Chiesi Farmaceutici S.p.A., Parma, Italy) is the first fully synthetic surfactant enriched by peptide analogues of two human surfactant proteins. We planned to assess safety and tolerability of CHF5633 and explore preliminary efficacy. DESIGN: Multicentre cohort study. PATIENTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sweet, David G, Turner, Mark A, Straňák, Zbyněk, Plavka, Richard, Clarke, Paul, Stenson, Ben J, Singer, Dominique, Goelz, Rangmar, Fabbri, Laura, Varoli, Guido, Piccinno, Annalisa, Santoro, Debora, Speer, Christian P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Archives of Disease in Childhood 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739829/
https://www.ncbi.nlm.nih.gov/pubmed/28465315
http://dx.doi.org/10.1136/archdischild-2017-312722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739829/
https://www.ncbi.nlm.nih.gov/pubmed/28465315
http://dx.doi.org/10.1136/archdischild-2017-312722

Ejemplares similares